Bainbridge Hannah E, Menten Martin J, Fast Martin F, Nill Simeon, Oelfke Uwe, McDonald Fiona
Department of Radiotherapy at The Royal Marsden NHS Foundation Trust, United Kingdom; The Institute of Cancer Research, United Kingdom.
Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Radiother Oncol. 2017 Nov;125(2):280-285. doi: 10.1016/j.radonc.2017.09.009. Epub 2017 Oct 4.
This study investigates the feasibility and potential benefits of radiotherapy with a 1.5T MR-Linac for locally advanced non-small cell lung cancer (LA NSCLC) patients.
Ten patients with LA NSCLC were retrospectively re-planned six times: three treatment plans were created according to a protocol for conventionally fractionated radiotherapy and three treatment plans following guidelines for isotoxic target dose escalation. In each case, two plans were designed for the MR-Linac, either with standard (∼7mm) or reduced (∼3mm) planning target volume (PTV) margins, while one conventional linac plan was created with standard margins. Treatment plan quality was evaluated using dose-volume metrics or by quantifying dose escalation potential.
All generated treatment plans fulfilled their respective planning constraints. For conventionally fractionated treatments, MR-Linac plans with standard margins had slightly increased skin dose when compared to conventional linac plans. Using reduced margins alleviated this issue and decreased exposure of several other organs-at-risk (OAR). Reduced margins also enabled increased isotoxic target dose escalation.
It is feasible to generate treatment plans for LA NSCLC patients on a 1.5T MR-Linac. Margin reduction, facilitated by an envisioned MRI-guided workflow, enables increased OAR sparing and isotoxic target dose escalation for the respective treatment approaches.
本研究探讨使用1.5T磁共振直线加速器(MR-Linac)对局部晚期非小细胞肺癌(LA NSCLC)患者进行放射治疗的可行性和潜在益处。
对10例LA NSCLC患者进行回顾性重新规划,共6次:根据传统分割放疗方案制定3个治疗计划,按照等毒性靶区剂量递增指南制定3个治疗计划。在每种情况下,为MR-Linac设计2个计划,计划靶体积(PTV)边缘分别采用标准(约7mm)或缩小(约3mm)的边缘,同时用标准边缘创建1个传统直线加速器计划。使用剂量体积指标或通过量化剂量递增潜力来评估治疗计划质量。
所有生成的治疗计划均满足各自的计划约束条件。对于传统分割治疗,与传统直线加速器计划相比,采用标准边缘的MR-Linac计划皮肤剂量略有增加。采用缩小边缘可缓解此问题,并减少其他几个危及器官(OAR)的受照剂量。缩小边缘还能实现更高的等毒性靶区剂量递增。
在1.5T MR-Linac上为LA NSCLC患者生成治疗计划是可行的。通过设想的MRI引导工作流程实现的边缘缩小,可为相应的治疗方法增加对OAR的保护并实现等毒性靶区剂量递增。